Login / Signup

Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.

Evangelos K OikonomouMarc A SuchardDarren K McGuireRohan Khera
Published in: Diabetes care (2022)
We present an evidence-based, machine learning-guided algorithm to personalize the prescription of SGLT2 inhibitors for patients with type 2 diabetes for ASCVD effects.
Keyphrases
  • machine learning
  • type diabetes
  • artificial intelligence
  • deep learning
  • big data
  • glycemic control
  • cardiovascular disease
  • insulin resistance